Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | KYNU | Q16719 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8436190 | 0.91 | SIRT2 (0.58) | ALDH1A1ALOX15CTSLCTSKSIRT2 | |
| SCHEMBL8436193 | 0.91 | SIRT2 (0.58) | ALDH1A1ALOX15CTSLCTSKSIRT2 | |
| SCHEMBL22637150 | 0.88 | KYNU (0.57) | ALDH1A1ALOX15CTSLCTSKSIRT2 | |
| SCHEMBL29262797 | 0.88 | KYNU (0.57) | ALDH1A1ALOX15CTSLCTSKSIRT2 | |
| SCHEMBL14673025 | 0.86 | ALDH1A1 (0.58) | ALDH1A1ALOX15CTSLCTSKCTSS | |
| SCHEMBL14673026 | 0.86 | ALDH1A1 (0.58) | ALDH1A1ALOX15CTSLCTSKCTSS | |
| SCHEMBL27626645 | 0.85 | FOLH1 (0.57) | ALDH1A1ALOX15CTSLCTSKSIRT2 | |
| SCHEMBL116479 | 0.85 | FOLH1 (0.57) | ALDH1A1ALOX15CTSLCTSKSIRT2 | |
| SCHEMBL329038 | 0.85 | CTSK (0.66) | ALDH1A1ALOX15CTSLCTSKSIRT2 | |
| SCHEMBL265783 | 0.85 | CTSK (0.66) | ALDH1A1ALOX15CTSLCTSKSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0959070-B1 | Process for the production of 3-amino-2-oxopyrrolidines, novel intermediates and their use | DEGUSSA (DE) | 2007-09-12 | — | — | EP | disclosed |
| US-6492541-B2 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | DEGUSSA-HULS AKTIENGESELLSCHAFT (DE) | 2002-12-10 | — | — | US | disclosed |
| US-20020045763-A1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | DEGUSSA-HULS AKTIENGENSELLSCHAFT | 2002-04-18 | — | — | US | disclosed |
| US-20010025109-A1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | DEGUSSA-HULS AKTIENGENSELLSCHAFT | 2001-09-27 | — | — | US | disclosed |
| US-6281364-B1 | CYCLIZATION | DEGUSSA-HULS AG (DE) | 2001-08-28 | — | — | US | disclosed |
| EP-0959070-A1 | Process for the production of 3-amino-2-oxopyrrolidines, novel intermediates and their use | Degussa-Hüls Aktiengesellschaft (DE) | 1999-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025109-A1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | AAAS, IL4I1, PGLS | ALDH1A1 2647/4885ALOX15 3626/4885CTSL 891/4885 |
| US-20020045763-A1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | AAAS, IL4I1, PGLS | ALDH1A1 2647/4885ALOX15 3626/4885CTSL 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.